JP2010539236A5 - - Google Patents

Download PDF

Info

Publication number
JP2010539236A5
JP2010539236A5 JP2010525827A JP2010525827A JP2010539236A5 JP 2010539236 A5 JP2010539236 A5 JP 2010539236A5 JP 2010525827 A JP2010525827 A JP 2010525827A JP 2010525827 A JP2010525827 A JP 2010525827A JP 2010539236 A5 JP2010539236 A5 JP 2010539236A5
Authority
JP
Japan
Prior art keywords
composition
actriia
fusion protein
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010525827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539236A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/010868 external-priority patent/WO2009038745A1/en
Publication of JP2010539236A publication Critical patent/JP2010539236A/ja
Publication of JP2010539236A5 publication Critical patent/JP2010539236A5/ja
Withdrawn legal-status Critical Current

Links

JP2010525827A 2007-09-18 2008-09-17 アクチビン−ActRIIa拮抗薬およびFSH分泌を低減または阻害するための使用 Withdrawn JP2010539236A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99439907P 2007-09-18 2007-09-18
PCT/US2008/010868 WO2009038745A1 (en) 2007-09-18 2008-09-17 Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013234827A Division JP2014031380A (ja) 2007-09-18 2013-11-13 アクチビン−ActRIIa拮抗薬およびFSH分泌を低減または阻害するための使用

Publications (2)

Publication Number Publication Date
JP2010539236A JP2010539236A (ja) 2010-12-16
JP2010539236A5 true JP2010539236A5 (esLanguage) 2012-11-01

Family

ID=40329024

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010525827A Withdrawn JP2010539236A (ja) 2007-09-18 2008-09-17 アクチビン−ActRIIa拮抗薬およびFSH分泌を低減または阻害するための使用
JP2013234827A Withdrawn JP2014031380A (ja) 2007-09-18 2013-11-13 アクチビン−ActRIIa拮抗薬およびFSH分泌を低減または阻害するための使用
JP2015219227A Withdrawn JP2016026225A (ja) 2007-09-18 2015-11-09 アクチビン−ActRIIa拮抗薬およびFSH分泌を低減または阻害するための使用
JP2017192704A Pending JP2017222725A (ja) 2007-09-18 2017-10-02 アクチビン−ActRIIa拮抗薬およびFSH分泌を低減または阻害するための使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013234827A Withdrawn JP2014031380A (ja) 2007-09-18 2013-11-13 アクチビン−ActRIIa拮抗薬およびFSH分泌を低減または阻害するための使用
JP2015219227A Withdrawn JP2016026225A (ja) 2007-09-18 2015-11-09 アクチビン−ActRIIa拮抗薬およびFSH分泌を低減または阻害するための使用
JP2017192704A Pending JP2017222725A (ja) 2007-09-18 2017-10-02 アクチビン−ActRIIa拮抗薬およびFSH分泌を低減または阻害するための使用

Country Status (7)

Country Link
US (4) US7960343B2 (esLanguage)
EP (2) EP2207562B1 (esLanguage)
JP (4) JP2010539236A (esLanguage)
CN (3) CN107412734A (esLanguage)
CA (1) CA2699936A1 (esLanguage)
HK (1) HK1199213A1 (esLanguage)
WO (1) WO2009038745A1 (esLanguage)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2551852T3 (es) * 2004-07-23 2015-11-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US8128933B2 (en) * 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR20160137665A (ko) * 2005-11-23 2016-11-30 악셀레론 파마 인코포레이티드 액티빈-actrⅱa 길항제 및 골 성장을 촉진하기 위한 이들의 용도
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
ES2396734T3 (es) * 2006-12-18 2013-02-25 Acceleron Pharma, Inc. Antagonistas de ACTIVINA-ACTRII y sus usos para tratar la anemia
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
JP5237970B2 (ja) * 2007-02-01 2013-07-17 アクセルロン ファーマ, インコーポレイテッド 乳癌を治療または予防するためのアクチビンActRIIaアンタゴニストおよび使用
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
JP5574711B2 (ja) * 2007-02-09 2014-08-20 アクセルロン ファーマ, インコーポレイテッド 癌患者における骨成長を促進するためのアクチビン−actriiaアンタゴニストおよびその使用
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US7960343B2 (en) 2007-09-18 2011-06-14 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
ES2852699T3 (es) * 2008-06-26 2021-09-14 Acceleron Pharma Inc Antagonistas de ActRIIb y usos para aumentar los niveles de glóbulos rojos
EP3363453A1 (en) 2008-06-26 2018-08-22 Acceleron Pharma Inc. Soluble actriia as activin-actriia antagonist for use in treating anemia or bone-related disorders
SI3750552T1 (sl) 2008-08-14 2023-10-30 Acceleron Pharma Inc. GDF pasti
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PT2370463T (pt) 2008-11-26 2016-11-04 Amgen Inc Variante estabilizada do receptor da activina iib
US8138142B2 (en) * 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
EP3845239A1 (en) 2009-06-08 2021-07-07 Acceleron Pharma Inc. Use of anti-actriib proteins for increasing thermogenic adipocytes
WO2010151426A1 (en) 2009-06-12 2010-12-29 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
EP3919068A1 (en) * 2009-09-09 2021-12-08 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof for promoting ed blood cell formation
JP5836961B2 (ja) * 2009-11-03 2015-12-24 アクセルロン ファーマ, インコーポレイテッド 脂肪肝疾患を処置するための方法
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
MX358358B (es) 2011-12-19 2018-08-15 Amgen Inc Polipeptidos de receptores de activina variantes y sus usos.
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
CN104981250A (zh) 2012-10-24 2015-10-14 细胞基因公司 用于治疗贫血的方法
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
CN105431455A (zh) 2013-02-01 2016-03-23 圣塔玛丽亚生物疗法公司 抗激活素a化合物对受试者的施用
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
TWI773117B (zh) 2014-12-03 2022-08-01 美商西建公司 活化素-actrii拮抗劑及治療貧血之用途
EP3256148A1 (en) 2015-02-12 2017-12-20 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
CA2983440C (en) 2015-04-22 2024-03-12 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
HK1252174A1 (zh) 2015-05-20 2019-05-17 细胞基因公司 使用II型活化素受体配体阱的用於β-地中海贫血的体外细胞培养方法
GB2554859A (en) 2016-10-04 2018-04-18 Johnson Matthey Plc NOx adsorber catalyst
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
JP7139326B2 (ja) 2016-11-10 2022-09-20 ケロス セラピューティクス インコーポレイテッド アクチビンIIa型受容体変異体および同変異体を含む医薬組成物
US11484573B2 (en) 2017-11-09 2022-11-01 Keros Therapeutics, Inc. Activin receptor type IIa variants and methods of use thereof
IL275936B2 (en) 2018-01-12 2025-09-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of using them
EP3790572A4 (en) 2018-05-09 2022-03-16 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
WO2021142191A1 (en) 2020-01-08 2021-07-15 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
CA3176735A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Activin receptor type ii chimeras and methods of use thereof
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Family Cites Families (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0637520B2 (ja) 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4973577A (en) 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides
US5092885A (en) 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
DE69114782T2 (de) 1990-08-08 1996-04-18 Takeda Chemical Industries Ltd Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff.
AU8761391A (en) 1990-09-13 1992-04-15 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
WO1992012717A2 (en) 1991-01-15 1992-08-06 A composition containing a tetracycline and use for inhibiting angiogenesis
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
CA2086327A1 (en) 1991-05-10 1992-11-11 Lawrence S. Mathews Cloning and recombinant production of receptor(s) of the activin/tgf- .beta. superfamily
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
WO1993000432A1 (en) 1991-06-25 1993-01-07 Genetics Institute, Inc. Bmp-9 compositions
US6692925B1 (en) 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
EP0679163A4 (en) 1993-01-12 1997-07-16 Univ Johns Hopkins Med GROWTH DIFFERENTIATION FACTOR-3.
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
ATE265529T1 (de) 1993-05-12 2004-05-15 Inst Genetics Llc Bmp-10 zusammensetzungen
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5831050A (en) 1993-06-07 1998-11-03 Creative Biomolecules, Inc. Morphogen cell surface receptor
ATE355369T1 (de) 1993-10-14 2006-03-15 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5658876A (en) * 1994-04-28 1997-08-19 The General Hospital Corporation Activin antagonists as novel contraceptives
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
EP0830459B1 (en) 1995-04-11 2007-01-24 The General Hospital Corporation Reverse two-hybrid systems
ES2206602T3 (es) 1995-10-23 2004-05-16 The Children's Medical Center Corporation Compuestos y metodos terapeuticos inhibidores de angiogenesis.
EP0771873A3 (en) 1995-10-27 1998-03-04 Takeda Chemical Industries, Ltd. Neuronal cell-specific receptor protein
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US6465431B1 (en) 1999-11-17 2002-10-15 Boston Life Sciences, Inc. Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis
US20050244867A1 (en) 1996-03-26 2005-11-03 Human Genome Sciences, Inc. Growth factor HTTER36
US6004780A (en) 1996-03-26 1999-12-21 Human Genome Sciences, Inc. Growth factor HTTER36
AU733303C (en) 1996-05-31 2002-08-08 Scripps Research Institute, The Methods and compositions useful for inhibition of angiogenesis
US7053263B2 (en) 1996-10-15 2006-05-30 The Regents Of The University Of California Mouse models of human prostate cancer progression
BR9712675A (pt) 1996-10-25 1999-10-19 Searle & Co Agonistas do receptor de eritropoietina circularmente permutados.
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6605699B1 (en) 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US6034062A (en) 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US6231880B1 (en) 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6372454B2 (en) 1997-08-29 2002-04-16 Human Genome Sciences, Inc. Nucleic acid molecules encoding Follistatin-3
US6953662B2 (en) 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
KR100473836B1 (ko) 1997-10-03 2005-03-07 츄가이 세이야꾸 가부시키가이샤 천연 인간형화 항체
US6475784B1 (en) 1997-11-14 2002-11-05 Valentis, Inc. Inhibition of angiogenesis by delivery of nucleic acids encoding anti-angiogenic polypeptides
US6569845B1 (en) 1997-12-26 2003-05-27 Mochida Pharmaceutical Co., Ltd. Neovascularization inhibitor containing dienogest as the active ingredient
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
EP1083896A4 (en) 1998-05-11 2002-09-11 Endowment For Res In Human Bio USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES
US6413513B1 (en) 1998-05-22 2002-07-02 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
US6395718B1 (en) 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
WO2000002902A1 (en) 1998-07-13 2000-01-20 Gill Parkash S Novel inhibitors of angiogenesis and tumor growth
WO2000003726A1 (en) 1998-07-14 2000-01-27 Bristol-Myers Squibb Company Lysine binding fragments of angiostatin
WO2000010507A2 (en) 1998-08-21 2000-03-02 The Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
CN1317967A (zh) 1998-09-17 2001-10-17 伊莱利利公司 蛋白质制剂
AU5502799A (en) 1998-09-22 2000-04-10 Long Yu New human growth differentiation factor encoding sequence and polypeptide encoded by such dna sequence and producing method thereof
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6548634B1 (en) 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6777205B1 (en) 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
EP1147413B1 (en) 1999-01-21 2006-04-05 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
US6537549B2 (en) * 1999-02-24 2003-03-25 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
EP1174149A1 (en) 1999-04-19 2002-01-23 Kyowa Hakko Kogyo Co., Ltd. Proliferation inhibitor for androgen-independent tumor
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
BR0015506A (pt) 1999-11-12 2002-07-23 Maxygen Holdings Ltd Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças
CN1250288C (zh) 1999-12-15 2006-04-12 研究发展基金会 作为抑制素受体的β聚糖及其用途
CA2395191A1 (en) 1999-12-23 2001-06-28 Tedman Ehlers Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
WO2001072829A2 (en) 2000-03-31 2001-10-04 Institut Pasteur Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
US6627424B1 (en) 2000-05-26 2003-09-30 Mj Bioworks, Inc. Nucleic acid modifying enzymes
AU2001269709A1 (en) 2000-07-19 2002-02-05 Eli Lilly And Company Nucleic acids, vectors, host cells, polypeptides, and uses thereof
US6632180B1 (en) 2000-09-07 2003-10-14 John H. Laragh Method for evaluating and treating hypertension
DE10045591A1 (de) 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
AU1325102A (en) 2000-10-16 2002-04-29 Phylos Inc Protein scaffolds for antibody mimics and other binding proteins
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
EP1345959B1 (en) 2000-11-20 2011-05-25 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
AU2002236558A1 (en) 2000-12-01 2002-06-11 Regents Of The University Of California Method and composition for modulating bone growth
US20030082233A1 (en) 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US20040132675A1 (en) 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
US7294472B2 (en) 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
US20040121008A1 (en) 2001-03-16 2004-06-24 Keiko Shiraishi Process for producing sustained release preparation
CA2444854A1 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
ATE446771T1 (de) 2001-05-24 2009-11-15 Zymogenetics Inc Taci-immunoglobulin-fusionsproteine
EP1390497A2 (en) 2001-05-25 2004-02-25 Genset Human cdnas and proteins and uses thereof
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
US6855344B2 (en) 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
CN100419425C (zh) 2001-07-17 2008-09-17 帝人株式会社 通过测定PPARδ激活作用筛选物质的方法和药剂
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US20060234918A1 (en) 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
US6998118B2 (en) 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
EP1573002A4 (en) 2002-02-11 2008-07-16 Genentech Inc ANTIBODY VARIANTS WITH FASTER ANTIGEN ASSOCIATION SPEEDS
KR20040094709A (ko) 2002-02-21 2004-11-10 와이어쓰 폴리스타틴 도메인을 포함하는 단백질
US20030219846A1 (en) 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
WO2003087162A2 (en) 2002-04-18 2003-10-23 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
WO2004016639A1 (en) 2002-08-16 2004-02-26 Wyeth Bmp-2 estrogen responsive element and methods of using the same
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2002953327A0 (en) 2002-12-12 2003-01-09 Monash University Methods of diagnosing prognosing and treating activin associated diseases and conditions
ATE419846T1 (de) 2003-02-07 2009-01-15 Prometic Biosciences Inc Fettsäuren mittlerer kettenlänge, glyceride und analoga als stimulatoren der erythropoiese
US20040197828A1 (en) 2003-03-26 2004-10-07 Gaddy Dana P. Method for diagnosis and treatment of bone turnover
US20070184052A1 (en) 2003-05-09 2007-08-09 Lin Herbert Y Soluble tgf-b type III receptor fusion proteins
KR20060026860A (ko) 2003-06-02 2006-03-24 와이어쓰 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (gdf8) 저해제의 용도
NZ544618A (en) 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
WO2005009460A2 (en) 2003-07-25 2005-02-03 Medexis, S.A. Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
WO2005070967A2 (en) 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
US7625867B2 (en) 2004-03-26 2009-12-01 Acceleron Pharma Inc. BMP-3 propeptides and related methods
US7459527B2 (en) 2004-03-31 2008-12-02 Xencor, Inc. BMP-7 variants with improved properties
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
EP1771557B1 (en) 2004-06-24 2014-12-31 Acceleron Pharma Inc. GDF3 Propeptides and Related Methods
ES2551852T3 (es) 2004-07-23 2015-11-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
US8617815B2 (en) 2004-08-05 2013-12-31 The Regents Of The University Of California Molecules with effects on cellular development and function
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
CA2581896C (en) 2004-09-29 2015-11-10 Mount Sinai School Of Medicine Of New York University Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
JP2008520207A (ja) 2004-11-16 2008-06-19 アヴィディア リサーチ インスティテュート タンパク質骨格およびその使用
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
EP2335719B1 (en) 2005-02-16 2015-06-24 The General Hospital Corporation Use of hemojuvelin fusion proteins to regulate hepcidin-mediated iron metabolism
WO2006115274A1 (ja) 2005-04-26 2006-11-02 Ajinomoto Co., Inc. 骨髄赤血球前駆細胞分化促進剤
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
JP2007099764A (ja) 2005-09-09 2007-04-19 Ajinomoto Co Inc 血糖低下剤
DK1931697T3 (da) 2005-09-28 2010-11-08 Zymogenetics Inc IL-17A og IL-17F-antagonister og fremgangsmåder til anvendelse af disse
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR20160137665A (ko) 2005-11-23 2016-11-30 악셀레론 파마 인코포레이티드 액티빈-actrⅱa 길항제 및 골 성장을 촉진하기 위한 이들의 용도
MX2008007324A (es) 2005-12-06 2009-03-04 Amgen Inc Usos de antagonistas de miostatina.
JP2009519984A (ja) 2005-12-20 2009-05-21 メルク フロスト カナダ リミテツド ステアロイル−補酵素δ−9デサチュラーゼ阻害剤としての芳香族複素環化合物
US20070161578A1 (en) 2005-12-21 2007-07-12 Hwa Joyce J Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
WO2007076127A2 (en) 2005-12-22 2007-07-05 Biogen Idec Ma Inc Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators
JP4925364B2 (ja) 2006-01-20 2012-04-25 ベックマン コールター, インコーポレイテッド 鉄欠乏を検出する方法
JP2009531280A (ja) 2006-01-25 2009-09-03 ウェルスタット セラピューティクス コーポレイション 代謝障害を処置するための化合物
NZ570100A (en) 2006-02-28 2011-01-28 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
EP2007813A2 (en) 2006-04-14 2008-12-31 Amgen Inc. Agonist erythropoietin receptor antibodies
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
JP2009536659A (ja) 2006-05-09 2009-10-15 ヘマクエスト・ファーマシューティカルズ,インコーポレーテッド 血液疾患の治療法
EP2048948B1 (en) 2006-07-21 2012-02-29 Lyne Laboratories, Inc. Liquid compositions of calcium acetate
GB0615129D0 (en) 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008060139A1 (en) 2006-11-17 2008-05-22 Erasmus University Medical Center Rotterdam Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
US20100003190A1 (en) 2006-12-08 2010-01-07 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
JP5632582B2 (ja) 2006-12-14 2014-11-26 中外製薬株式会社 抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
ES2396734T3 (es) 2006-12-18 2013-02-25 Acceleron Pharma, Inc. Antagonistas de ACTIVINA-ACTRII y sus usos para tratar la anemia
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
JP5237970B2 (ja) * 2007-02-01 2013-07-17 アクセルロン ファーマ, インコーポレイテッド 乳癌を治療または予防するためのアクチビンActRIIaアンタゴニストおよび使用
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
JP5574711B2 (ja) 2007-02-09 2014-08-20 アクセルロン ファーマ, インコーポレイテッド 癌患者における骨成長を促進するためのアクチビン−actriiaアンタゴニストおよびその使用
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
CA2685306A1 (en) 2007-06-01 2008-12-11 Wyeth Methods and compositions for modulating bmp-10 activity
WO2009009059A1 (en) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
CA2685540C (en) 2007-08-03 2018-10-16 Graham Michael Wynne Drug combinations for the treatment of duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0715938D0 (en) 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
WO2009025651A1 (en) 2007-08-17 2009-02-26 University Of Maine System Board Of Trustees Biologically active peptide and method of using the same
US20100279409A1 (en) 2007-09-13 2010-11-04 Neil Robson Method for modifying celluar immune resonse by modulating activin activity
US7960343B2 (en) 2007-09-18 2011-06-14 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
EP2220118A2 (en) 2007-11-21 2010-08-25 Amgen Inc. Wise binding antibodies and epitopes
US8507501B2 (en) 2008-03-13 2013-08-13 The Brigham And Women's Hospital, Inc. Inhibitors of the BMP signaling pathway
AU2009244308A1 (en) 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
WO2009137075A1 (en) 2008-05-06 2009-11-12 Acceleron Pharma Inc. Anti-activin antibodies and uses for promoting bone growth
EP3363453A1 (en) 2008-06-26 2018-08-22 Acceleron Pharma Inc. Soluble actriia as activin-actriia antagonist for use in treating anemia or bone-related disorders
ES2852699T3 (es) 2008-06-26 2021-09-14 Acceleron Pharma Inc Antagonistas de ActRIIb y usos para aumentar los niveles de glóbulos rojos
SI3750552T1 (sl) 2008-08-14 2023-10-30 Acceleron Pharma Inc. GDF pasti
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010059861A1 (en) 2008-11-20 2010-05-27 University Of Southern California Compositions and methods to modulate hair growth
PT2370463T (pt) 2008-11-26 2016-11-04 Amgen Inc Variante estabilizada do receptor da activina iib
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
US8110355B2 (en) 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
MX2011011352A (es) 2009-04-27 2011-11-18 Novartis Ag Composiciones y metodos para aumentar el crecimiento muscular.
EP3845239A1 (en) 2009-06-08 2021-07-07 Acceleron Pharma Inc. Use of anti-actriib proteins for increasing thermogenic adipocytes
WO2010151426A1 (en) 2009-06-12 2010-12-29 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
CN105561295B (zh) 2009-08-13 2020-03-20 阿塞勒隆制药公司 Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
EP3919068A1 (en) 2009-09-09 2021-12-08 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof for promoting ed blood cell formation
JP5836961B2 (ja) 2009-11-03 2015-12-24 アクセルロン ファーマ, インコーポレイテッド 脂肪肝疾患を処置するための方法
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
DK2726099T3 (en) 2011-07-01 2018-11-05 Novartis Ag Method of treating metabolic disorders
ES2869168T3 (es) 2011-10-17 2021-10-25 Acceleron Pharma Inc Composiciones para tratar la mielofibrosis
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
WO2013063536A1 (en) 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
MX358358B (es) 2011-12-19 2018-08-15 Amgen Inc Polipeptidos de receptores de activina variantes y sus usos.
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9102212B2 (en) 2012-05-14 2015-08-11 Paccar Inc Fresh air system for heavy duty vehicle cab/sleeper combination
US9663569B2 (en) 2012-06-14 2017-05-30 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Use of blocking agents of bone morphogenic protein (BMP) signalling for the treatment of neuroinflammatory and neurodegenerative diseases
JP6298762B2 (ja) 2012-07-02 2018-03-20 協和発酵キリン株式会社 抗bmp9抗体を有効成分とする、腎性貧血、がん性貧血などの貧血に対する治療剤
EP3608419B1 (en) 2012-10-24 2025-03-26 Celgene Corporation Biomarker for use in treating anemia
CN104981250A (zh) 2012-10-24 2015-10-14 细胞基因公司 用于治疗贫血的方法
WO2014064292A1 (en) 2012-10-26 2014-05-01 Universite Pierre Et Marie Curie (Paris 6) A method for preventing or treating atrial fibrillation
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
WO2014074823A1 (en) 2012-11-08 2014-05-15 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
US20150328249A1 (en) 2012-12-11 2015-11-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Modulation of myofiber repair by anti-myostatin strategies and/or ppar gamma ligands, alone or in combination with stem cells, for the therapy of critical limb ischemia and other ischemic processes affecting the skeletal muscle
US20140220033A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an Anti-Activin-A Compound to a Subject
ES2692363T3 (es) 2013-03-14 2018-12-03 Translate Bio, Inc. Composiciones terapéuticas de ARNm y su uso para tratar enfermedades y trastornos
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素a之抗體及其用途
BR112016002198A2 (pt) 2013-08-14 2017-09-12 Novartis Ag métodos de tratamento de miosite por corpos de inclusão esporádica
CA2932463A1 (en) 2013-12-16 2015-06-25 Paranta Biosciences Limited Method of diagnosis and treatment
WO2015108972A1 (en) 2014-01-14 2015-07-23 Santa Maria Biotherapeutics, Inc. Activin inhibitor response prediction and uses for treatment
EP3100056A2 (en) 2014-01-27 2016-12-07 Novartis AG Biomarkers predictive of muscle atrophy, method and use
JP6601687B2 (ja) 2014-03-31 2019-11-06 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
US20170202909A1 (en) 2014-06-13 2017-07-20 Santa Maria Biotherapeutics, Inc. Formulated Receptor Polypeptides and Related Methods

Similar Documents

Publication Publication Date Title
JP2010539236A5 (esLanguage)
Mujoo et al. Regulation of ERBB3/HER3 signaling in cancer
JP6282296B2 (ja) Egfrを標的とする癌の組み合わせ治療方法
JP2010518006A5 (esLanguage)
EP3735267B1 (en) Adminsitration of multiple boluses of [6r] mthf in a 5-fluorouracil-based chemotherapy
RU2012129353A (ru) АНТАГОНИСТЫ АКТИВИНА-ActRIIA И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
EP3042669B1 (en) Antitumor agent and antitumor effect enhancer
KR20140053865A (ko) 항-erbb3제를 포함하는 조합 요법
US20220249621A1 (en) TREATMENT OF CANCERS USING sEphB4-HSA FUSION PROTEINS
CN117899079A (zh) 癌症的治疗方法
JP2020512978A5 (esLanguage)
EP3493847A2 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
MX2013015333A (es) Anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológgicos.
KR20220024821A (ko) 악성 종양의 치료 방법
US20230116137A1 (en) Methods for treating colorectal and metastatic colorectal cancers
AU2023206004A1 (en) Combination of an immunocytokine comprising il-12 and a kinase inhibitor
KR102558988B1 (ko) 항암제 내성을 완화하고 항암제의 민감성을 강화하기 위한 약학적 조성물 및 그 용도
EP4365187A1 (en) Peptide having anticancer activity, and use thereof
Jeremić et al. Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients
Ramanathan Alternative dosing schedules for cetuximab: a role for biweekly administration?
WO2018079701A1 (ja) ラクトフェリン活性を有するタンパク質を含む、抗ガン治療補助剤
TW202508573A (zh) 用於治療癌症之組合療法
Bandari International Association for the Study of Lung Cancer (IASLC)–23rd World Conference on Lung Cancer (WCLC 2022). Vienna–August 6-9, 2022
Czyżykowski et al. Palliative systemic treatment of patients with pancreatic cancer—should reimbursement of nab-paclitaxel change the current management paradigm?
HK40040066B (en) Administration of multiple boluses of [6r] mthf in a 5-fluorouracil-based chemotherapy